🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03909477
Recruiting Observational

Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking

NCT03909477 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2022-06-01
Last updated
2025-08-15

Condition(s) studied

Cannabis UseCannabis SmokingMarijuana SmokingMarijuana Usage

Investigational drug(s) / intervention(s)

Hyperpolarized Xenon-129 MRI of the lungsComputed Tomography (CT)Pulmonary Function Tests (PFTs)Six Minute Walk Test (6MWT)Cardiopulmonary exercise testing (CPET)Sputum analysisBlood analysis

Hyperpolarized Xenon-129 MRI of the lungs: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

Computed Tomography (CT): Participants will undergo a CT scan of the thoracic cavity

Pulmonary Function Tests (PFTs): Participants will have their lung function evaluated using PFTs

Six Minute Walk Test (6MWT): Participants \>35 years of age will perform the six minute walk test as a measure of exercise capacity

Cardiopulmonary exercise testing (CPET): Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity

Sputum analysis: Participants will provide a sputum sample that will be analysed for eosinophils

Blood analysis: Participants will have their blood drawn and analysed for eosinophil count.

Study summary

This is a longitudinal study of the long-term health impact of cannabis smoking on the lungs. Participants will be followed over a period of 3 years, and impacts of cannabis smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature * Provision of written, informed consent prior to any study specific procedures * Males and females aged 18-85 * Current or former cannabis smoker (medicinal or recreational) with or without concurrent tobacco smoking history * Participant is able to perform reproducible pulmonary function testing (i.e. the 3 best acceptable spirograms have Forced Expiratory Volume in 1 second (FEV1) values that do not vary more than 150 millilitres) * Participant is able to perform a breathhold for 16s * FEV1 \> 25% predicted * Forced Vital Capacity (FVC) \> 25% predicted and \>0.5 litres Exclusion Criteria: * Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand written material * Participant is medically unstable in the opinion of the Principal Investigator * Participant has a daytime room air oxygen saturation \<90% while lying supine * Participant is unable to perform spirometry or plethysmography maneuvers * Patient is pregnant at time of enrolment * In the opinion of the investigator, patient suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia * Patient has implanted mechanically, electrically or magnetically activated device or any metal in their body, which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) - at the discretion of the MRI Technologist.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre London Ontario Recruiting

More Western University, Canada trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03909477 on ClinicalTrials.gov ↗ ← All trials in Canada